Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL

Blachly, J. S., Stephens, D. M., Ye, J. C., Lamanna, N., Jain, N., Niesman, M., Zhang, K., & Woyach, J. A. (2022). Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL. Blood, 140(Supplement 1), 2324–2325. https://doi.org/10.1182/blood-2022-171203

Authors:

James S. Blachly

Deborah M. Stephens

J Christine Ye

Nicole Lamanna

Nitin Jain

Michael R. Niesman

Kai Zhang

Jennifer A. Woyach

Affiliated Authors:

Nicole Lamanna

Columbia Affiliation: